Clazosentan actelion

Current Opinion in Investigational Drugs

Volumn 7, Issue 3, 2006, Pages 272-281

  Uhlmann, Dirk ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATRASENTAN; AXV 034; AXV 343434; BOSENTAN; CLAZOSENTAN; DARUSENTAN; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; PAPAVERINE; PLACEBO; TBC 3711; UNCLASSIFIED DRUG;

ANTIHYPERTENSIVE ACTIVITY; BLOOD DISEASE; BRAIN INFARCTION; BRAIN ISCHEMIA; BRAIN VASOSPASM; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DISEASE MODEL; DOSE RESPONSE; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SOLUBILITY; DRUG SPECIFICITY; DRUG SYNTHESIS; HEART DISEASE; HEMODYNAMICS; HEPATOBILIARY DISEASE; HUMAN; HYPERTENSION; HYPOTENSION; INFECTION; KIDNEY BLOOD FLOW; METABOLIC DISORDER; NEUROLOGIC DISEASE; NONHUMAN; RESPIRATORY TRACT DISEASE; REVIEW; STRUCTURE ACTIVITY RELATION; SUBARACHNOID HEMORRHAGE; TACHYCARDIA; TOXICITY TESTING; VASCULAR DISEASE; VASODILATATION;

CLINICAL TRIALS, PHASE III; DIOXANES; ENDOTHELIN-1; HUMANS; MOLECULAR CONFORMATION; PYRIDINES; PYRIMIDINES; SUBARACHNOID HEMORRHAGE; SULFONAMIDES; TETRAZOLES; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASOSPASM, INTRACRANIAL;

EID: 33644947897     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Ishikawa K, Ihara M, Noguchi K, Mase T, Mino N, Saeki T, Fukuroda T, Fukami T, Ozaki S, Nagase T, Nishikibe M, Yano M PROC NATL ACAD SCI USA 1994 91 11 4892-4896
2. Characterization of receptors mediating vascular responses to endothelin-1 in the conscious rat. Filep JG, Clozel M, Foumier A, Foldes-Filep E BR J PHARMACOL 1994 113 3 845-852
3. Systemic administration of an inhibitor of endothelin-converting enzyme for attenuation of cerebral vasospasm following experimental subarachnoid hemorrhage. Caner HH, Kwan AL, Arthur A, Jeng AY, Lappe RW, Kassell NF, Lee KS J NEUROSURG 1996 85 5 917-922
4. New developments in the understanding of cerebral vasoregulation and vasospasm: The endothelin-nitric oxide network. Ehrenreich H, Schilling L CLEVEL CLIN J MED 1995 622 105-116
5. Endothelins: Molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Rubanyi GM, Polokoff MA PHARMACOL REV 1994 46 3 325-415
6. The endothelin antagonist Ro-61-1790 attenuates focal cerebral ischemic injury. Davison DA, Hallenbeck JM, Spatz M STROKE 1998 29 1 323
7. Ro-61-1790, a new hydrosoluble endothelin antagonist: General pharmacology and effects on experimental cerebral vasospasm. Roux S, Breu V, Giller T, Neidhart W, Ramuz H, Coassolo P, Clozel JP, Clozel M J PHARMACOL EXP THER 1997 283 3 1110-1118
8. Vanguard takes over compound for renal failure from Roche. BIOWORLD INT 1998 3 36 2
9. Vanguard Medica to collaborate with Roche on endothelin antagonist development programme. Vanguard Medics PRESS RELEASE 1998 September 07
10. Prevention of vasospasm after subarachnoid hemorrhage in dogs by continuous intravenous infusion of PD156707. Macdonald RL, Johns L, Lin G, Marton LS, Hallak H, Marcoux F, Kowalczuk A NEUROL MED CHIR 1998 38 Suppl 138-145
11. In vitro characterization and in vivo action after brain trauma of a new endothelin receptor-A antagonist: RO 61-1790. Hortobagyi T, Gorlch C, Benyo Z, Wahl M FUNDAM CLIN PHARMACOL 1999 13 Suppl 1 PS154
12. A receptor antagonist on neuronal injury in global ischemia. Sugano H, Ohara Y, McCarron RM, Hallenbeck JM, Spatz M ABSTR SOC NEUROSCI 1999 25 1 Abs 128.8
13. Molecular and cellular mechanism of endothelin regulation. Implications for vascular function. Masaki T, Kimura S, Yanagisawa M, Goto K CIRCULATION 1991 844 1457-1468
14. Molecular characterization of endothelin receptors. Sakurai T, Yanagisawa M, Masaki T TRENDS PHARMACOL SCI 1992 13 3 103-108
15. Identification and characterization of two isoforms of an endothelin-converting enzyme-1. Shimada K, Takahashi M, Ikeda M, Tanzawa K FEBS LETT 1995 371 2 140-144
16. Vernalis Group plc's interim results for the six months ended 30 June 2000. Vemalis Group plc PRESS RELEASE 2000 September 19
17. American Chemical Society - 223rd National Meeting (Part IV) - Overnight report, Orlando, FL, USA. Eyles A IDDB MEETING REPORT 2002 April 7-11
18. Axovan secures CHF 30 million to drive GPCR platform. Axovan Ltd PRESS RELEASE 2002 April 22
19. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T NATURE 1988 332 6163 441-415
20. Actelion starts acquisition of Axovan for $45.4 million. Actelion Ltd PRESS RELEASE 2003 September 30
21. Actelion confirmation of Axovan acquisition. Actelion Ltd COMPANY COMMUNICATION 2004 February 09
22. Annual Report 2003 - Actelion Ltd. Actelion Ltd ANNUAL REPORT 2004 March 02
23. Actelion's clazosentan enters vasospasm phase IIb/III trial. Actelion Ltd PRESS RELEASE 2004 December 23
24. Actelion's drug lowers incidence and severity of vasospasm. Actelion Ltd PRESS RELEASE 2005 July 04
25. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: A randomized, double-blind, placebo-controlled, multicenter, phase IIa study. Vajkoczy P, Meyer B, Weidauer S, Raabe A, Thome C, Ringel F, Breu V, Schmiedek P J NEUROSURG 2005 103 1 9-17
26. Cerebrovascular characterization of clazosentan, the first nonpeptide endothelin receptor antagonist shown to be clinically effective for the treatment of cerebral vasospasm. Part II: Effect on endothelin(B) receptor-mediated relaxation. Vatter H, Zimmermann M, Tesanovic V, Raabe A, Seifert V, Schilling L J NEUROSURG 2005 102 6 1108-1114
27. Cerebrovascular characterization of clazosentan, the first nonpeptide endothelin receptor antagonist clinically effective for the treatment of cerebral vasospasm. Part I: Inhibitory effect on endothelin(A) receptor-mediated contraction. Vatter H, Zimmermann M, Tesanovic V, Raabe A, Schilling L, Seifert V J NEUROSURG 2005 102 6 1101-1107
28. Effects of endothelin-1 and endothelin-1-receptor blockade on renal function in humans. Vuurmans JLT, Boer P, Koomans HA NEPHROL DIAL TRANSPLANT 2004 19 11 2742-2746
29. Effects of endothelin-1 and endothelin-1 receptor blockade on cardiac output, aortic pressure, and pulse wave velocity in humans. Vuurmans TJL, Boer P, Koomans HA HYPERTENSION 2003 41 6 1253-1258
30. Protective effects of endothelin receptor antagonists in dogs with aortic cross-clamping. Roux S, Qiu C, Sprecher U, Osterwalder R, Clozel JP J CARDIOVASC PHARMACOL 1999 34 2 199-205
31. Protective effects of endothelin receptor antagonists in experimental aortic cross clamping. Roux SP, Qiu C, Sprecher U, Osterwalder R CIRCULATION 1998 98 17 Suppl I33 1
32. Expression of the potent vasoconstrictor endothelin in the human central nervous system. Lee ME, de la Monte SM, Ng SC, Bloch KD, Quertemous T J CLIN INVEST 1990 86 1 141-147
33. A vasoactive peptide, endothelin-3, is produced by and specifically binds to primary astrocytes. Ehrenreich H, Kehrl JH, Anderson W, Rieckmann P, Vitkovic L, Coligan JE, Fauci AS BRAIN RES 1991 538 1 54-58
34. Release of endothelin from porcine aorta. Inhibition by endothelium derived nitric oxide. Boulanger C, Luscher TF J CLIN INVEST 1990 85 2 587-590
35. Secretion of immunoreactive endothelin-1 by capillary and microvascular endothelium of human brain. Bacic F, Uematsu S, McCarron RM, Spatz M NEUROCHEM RES 1992 17 7 699-702
36. Effects of endothelin and vasopressin on cerebral blood vessels. Faraci FM AM J PHYSIOL 1989 257 3 Pt 2 H799-H803
37. Endothelin acts in feline and canine cerebral arteries from the adventitial side. Mima T, Yanagisawa M, Shigeno T, Saito A, Goto K, Takakura K, Masaki T STROKE 1989 20 11 1553-1556
38. Endothelins and the cerebral circulation. Salons JB, Torregrosa G, Alborch E CEREBRAL BRAIN METAB REV 1995 7 2 131-152
39. Endothelin concentrations in patients with aneurysmal subarachnoid hemorrhage. Correlation with cerebral vasospasm, delayed ischemic neurologic deficits, and volume of hematoma. Seifert V, Loffler BM, Zimmermann M, Roux S, Stolke D J NEUROSURG 1995 82 1 55-62
40. Characterization of the contractile and relaxant action of the endothelin-1 precursor, big endothelin-1, in the isolated rat basilar artery. Schilling L, Vatter H, Mursch K, Ehrenreich H, Schmiedek P PEPTIDES 2000 21 1 91-99
41. Contractile responses to endothelin in feline cortical vessels in situ. Robinson MJ, McCulloch J J CEREB BLOOD FLOW METAB 1990 10 2 285-289
42. Prevention of cerebral vasospasm after experimental subarachnoid hemorrhage by RO 47-0203, a newly developed orally active endothelin receptor antagonist. Zimmermann M, Seifert V, Loffler BM, Stolke D, Stenzel W NEUROSURGERY 1996 38 1 115-120
43. Efficacy and safety of the endothelin receptor antagonist TAK-044 in treating subarachnoid hemorrhage: A report by the steering committee on behalf of the UK/Netherlands/Eire TAK-044 Subarachnoid Hemorrhage Study Group. Shaw MD, Vermeulen M, Murray GD, Pickard JD, Bell BA, Teasdale GM J NEUROSURG 2000 93 6 992-997
44. Human endothelin subtype A receptor enhancement during tissue culture via de novo transcription. Hensen-Schwartz J, Nordström C-H, Edvinsson L NEUROSURGERY 2002 50 1 127-135
45. Surgical risk as related to time of intervention in the repair of intracranial aneurysms. Hunt WE, Hess RM J NEUROSURG 1968 28 1 14-20
46. A receptor antagonist Ro 61-1790 reduces lesion volume after cold injury in the rat. Gorlach C, Hortobagyi T, Hortobagyi S, Benyo Z, Wahl M PFLUGERS ARCH 2001 441 6 844-849
47. Cerebral arterial spasm - a controlled trial of nimodipine in patients with subarachnoid hemorrhage. Allen GS, Ahn HS, Preziosi TJ, Battye R, Boone SC, Boone SC, Chou SN, Kelly DL, Weir BK, Crabbe RA, Lavik PJ, Rosenbloom SB, Dorsey FC, Ingram CR, Mellits DE, Bertsch LA, Boisvert DP, Hundley MB, Johnson RK, Strom JA, Transou CR N ENGL J MED 1983 308 11 619-624
48. Effect of intrathecal fibrinolytic therapy on clot lysis and vasospasm in patients with aneurysmal subarachnoid hemorrhage. Ohman J, Servo A, Heiskanen O J NEUROSURG 1991 75 2 197-201
49. Prospective, randomized, double-blind trial of BQ-123 and bosentan for prevention of vasospasm following subarachnoid hemorrhage in monkeys. Hino A, Weir BK, Macdonald RL, Thisted RA, Kim CJ, Johns LM J NEUROSURG 1995 83 3 503-509
50. A receptor mRNA expression in a canine subarachnoid hemorrhage model. Itoh S, Sasaki T, Asai A, Kuchino Y J NEUROSURG 1994 81 5 759-764
51. European Biotech in focus. Hermann M, Bennett S, Parkes R, Rivela J ING BANK NV 2005 1-56
52. Aneurysmal subarachnoid hemorrhage. Suarez JI, Tarr RW, Selman WR N ENGL J MED 2006 354 4387-396
53. Subarachnoid hemorrhage. Newton TR, Oman JK, Lavine S INTERNET SITE 2005 December 19
54. Endothelin receptors in gastrointestinal smooth muscle. Huang SC CURR PROTEIN PEPTIDE SCI 2005 6 6 547-557